**Supplementary Table 4**

|  |
| --- |
| **Clinical characteristics (n=20)** |
| **Archival (castration-sensitive) biopsy** |
| **Histology (N, %)**Adenocarcinoma  | 20, 100% |
| **Gleason score (N, %)**<77>7NR | 1, 5%3, 15%15, 75%1, 5% |
| **Metastatic at diagnosis (N, %)**M0M1NR | 7, 35%12, 60%1, 5% |
| **Treatment intent (N, %)**RadicalPalliative | 6, 30%14, 70% |
| **Paired metastatic castration-resistant biopsy** |
| **Biopsy site (N, %)**Bone marrowLymph nodeOther | 9, 45%8, 40%3, 15% |
| **Systemic therapies prior to biopsy^**1234 | 6, 30%7, 35%4, 20%3, 15% |
| **AR targeting therapy prior to biopsy**Post abirateronePost enzalutamidePost abiraterone and enzalutamide | 9, 45%7, 35%4, 20% |

**Clinical characteristics of prostate cancer patients with matched diagnostic (archival) castration-sensitive and metastatic castration-resistant tissue biopsies.**

N – number, NR – not recorded, AR – androgen receptor, ^ - systemic therapies include docetaxel, cabazitaxel, abiraterone and enzalutamide